image: Figure 1: History and Leadership of WIN Consortium in 2024.
(A) Leadership History of WIN Consortium, (B) Current WIN Consortium leadership.
Credit: Copyright: © 2025 El-Deiry et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
“Our vision is to accelerate the future of precision oncology care.”
BUFFALO, NY – March 18, 2025 – A new precision oncology paper was published in Oncotarget, Volume 16, on March 12, 2025, titled “Worldwide Innovative Network (WIN) Consortium in Personalized Cancer Medicine: Bringing next-generation precision oncology to patients.”
Led by Oncotarget Editor-in-Chief Dr. Wafik S. El-Deiry and a global team of researchers, this special publication highlights the groundbreaking work of the Worldwide Innovative Network (WIN) Consortium, a global collaboration dedicated to transforming cancer care through personalized medicine. By leveraging artificial intelligence (AI), molecular profiling, and innovative clinical trials, WIN is helping clinicians tailor treatments to each patient’s unique cancer profile—moving beyond the traditional one-size-fits-all approach.
The WIN Consortium is a fast-moving, non-profit organization bringing together nearly 40 academic, industry, and research institutions, along with patient advocacy groups, across 18 countries and five continents. Founded in 2010 in France by Dr. John Mendelsohn (MD Anderson Cancer Center) and Dr. Thomas Tursz (Gustave Roussy), WIN has been led by different renowned experts. Currently under Dr. El-Deiry’s leadership, WIN continues to break barriers in cancer research, ensuring cutting-edge treatments reach patients worldwide.
“The WIN global consortium is ready to take up the challenge by bringing the best possible Precision Oncology trial to patients.”
One of WIN’s most significant contributions is the development of N-of-1 clinical trials, a revolutionary approach that personalizes cancer treatment based on a patient’s specific tumor characteristics. Unlike traditional trials that test drugs on large groups, N-of-1 trials focus on finding the best therapy for an individual patient using AI-driven algorithms, genomic analysis, and real-world data. WIN’s WINTHER trial was one of the first to use both DNA and RNA analysis to match patients with the most effective therapies, while the WINGPO trial builds on this approach by integrating AI and liquid biopsies to refine treatment selection. These innovations are helping clinicians make more precise treatment decisions and improving outcomes for cancer patients.
While advancing research, the WIN Consortium is also addressing major challenges in precision oncology, including drug accessibility, regulatory barriers, and disparities in global healthcare. By working closely with governments, pharmaceutical companies, and advocacy organizations, WIN is aiming to ensure that life-saving treatments are accessible to all patients, regardless of location or financial status.
WIN’s mission is clear: to accelerate the future of precision oncology by delivering the latest scientific advancements into real-world cancer care. As the field continues to evolve, WIN remains at the forefront, developing next-generation trials and leveraging AI-driven insights to improve patient outcomes. Through global collaboration and groundbreaking research, the WIN Consortium is shaping a future where every cancer patient receives the most effective, personalized treatment possible.
Continue reading: DOI: https://doi.org/10.18632/oncotarget.28703
Correspondence to: Wafik S. El-Deiry — wafik@brown.edu
Keywords: cancer, precision oncology, N-of-1 basket trials, AI algorithms, digital pathology, drug access
Click here to sign up for free Altmetric alerts about this article.
About Oncotarget:
Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.
Oncotarget is indexed and archived by PubMed/Medline, PubMed Central, Scopus, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science).
To learn more about Oncotarget, visit Oncotarget.com and connect with us on social media:
X
Facebook
YouTube
Instagram
LinkedIn
Pinterest
Spotify, and available wherever you listen to podcasts
Click here to subscribe to Oncotarget publication updates.
For media inquiries, please contact media@impactjournals.com.
Oncotarget Journal Office
6666 East Quaker St., Suite 1
Orchard Park, NY 14127
Journal
Oncotarget
Method of Research
News article
Subject of Research
Not applicable
Article Title
Worldwide Innovative Network (WIN) Consortium in Personalized Cancer Medicine: Bringing next-generation precision oncology to patients
Article Publication Date
12-Mar-2025
COI Statement
– W.S.E-D. is Chair of the Worldwide Innovative Network (WIN) Association – WIN Consortium and Scientific Founder of Oncoceutics, Inc (acquired by Chimerix, Inc), SMURF-Therapeutics, and p53-Therapeutics. He is receiving or has received recent funding from NIH/NCI, American Cancer Society, The Warren Alpert Foundation, AACR-Novocure, D&D Phramatech, Chimerix, AstraZeneca, and Actuate Therapeutics. W.S.E-D. serves on the Executive Committee of the Caris Life Sciences Precision Oncology Alliance, and is co-Editor-in-Chief of Oncotarget, the journal that invited this manuscript as the inaugural “Special Article” in a Collection of articles on Precision Oncology”. – First author W.S.E-D. was not involved in the review of this manuscript or the decision to accept it. – C.B. and F.W. are full time employees of Worldwide Innovative Network (WIN) Association – WIN Consortium. – S.M. receives consulting honoraria from Worldwide Innovative Network (WIN) Association – WIN Consortium. – R.K. has received research funding from Boehringer Ingelheim, Debiopharm, Foundation Medicine, Genentech, Grifols, Guardant, Incyte, Konica Minolta, Medimmune, Merck Serono, Omniseq, Pfizer, Sequenom, Sysmex, Takeda, and TopAlliance and from the NCI; as well as consultant and/or speaker fees and/or advisory board/consultant for Actuate Therapeutics, AstraZeneca, Bicara Therapeutics, Inc., Biological Dynamics, Caris, Daiichi, Datar Cancer Genetics, EISAI, EMD Serono, EOM Pharmaceuticals, Iylon, Jackson Laboratories, LabCorp, Lanauria Therapeutics, Merck, NeoGenomics, Neomed, Pfizer, Precirix, Prosperdtx, Quanta Therapeutics, Recordati, Regeneron, Roche, TD2/Volastra, Turning Point Therapeutics, X-Biotech; has an equity interest in CureMatch Inc.; serves on the Board of CureMatch and CureMetrix and XZOM, and is a co-founder of CureMatch. – S.A.M. is a co-founder and Scientific Advisory Board Member of Sathgen Therapeutics, OneCellGen and Iylon Precision Oncology. – Pi.S. receives consulting honoraria from HTG Molecular Diagnostics, Inivata, ArcherDx, Bristol Myer Squibb, Roche Molecular Diagnostics; research funding from Roche, AstraZeneca, Novartis, BMS Foundation, Illumina, and his institution from Omicure; travel and accommodation support from Illumina, Bristol Myer Squibb, AstraZeneca, Roche. – J.L.W. receives consulting honoraria from Westat and The Lewin Group; has ownership in HemOnc.org LLC, all outside the submitted work. – R.A.M. receives consulting honoraria from Novartis, Sierra Oncology, Genentech, Sierra, Bleupring, Geron, Telios, CTI, Incyte, Bristol Myer Squibb, Abbvie, GlaxoSmithKline, Morphosys, Huron. – C.W.’s spouse is an employee of Roche/Genentech. C.W. has received research funding from Tempus, LabCorp, GeneDx, Ignite Proteomics, GlaxoSmithKline, Takeda, Sanofi, and Novartis. – R.L.S. serves as PI of the ASCO TAPUR study which is supported by research grants to ASCO from the following companies: Bayer, Boehringer-Ingelheim, Bristol Myers Squibb, Genentech, Lilly, Merck, Pfizer, Seagen, Taiho. R.L.S. serves on the Board of Directors and has stock of Leap Therapeutics; also serves on the Board of Clarified Precision Medicine (stock options). R.L.S. is a compensated advisor to Cellworks, Flatiron Health, Illumina, ZephyrAI. R.L.S. is compensated as chair of a DSMB for Toray Pharmaceuticals. – R.R.R. is an advisor to Tessellate Bio BV and Rejuveron Telomere Therapeutics. – A.H.C. reports financial interests in Merus, (expert testimony, personal); and institutional Research Grant from Gilead. A.H.C. has received travel support from Bristol Myers Squibb, Kyowa Kirin, Merck Serono. – S.L.G. reports stock ownership (current, personal) in HCA Healthcare; Consulting (all relationships ended, personal) from Pfizer, SeaGen, AstraZeneca, DaiichiSankyo, Gilead Sciences, Menarini Stemline, Genentech, Novartis, Lilly/Loxo@Lilly. S.L.G. reports institutional research funding from AstraZeneca/Daiichi Sankyo, Novartis, Daiichi Sankyo, Lilly, Roche. – J.T. reports personal financial interest in form of scientific consultancy role for Accent Therapeutics, Alentis Therapeutics, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Cartography Biosciences, Chugai, Daiichi Sankyo, F. Hoffmann-La Roche Ltd, Genentech Inc, Lilly, Menarini, Merus, MSD, Novartis, Ono Pharma USA, Peptomyc, Pfizer, Pierre Fabre, Quantro Therapeutics, Scandion Oncology, Scorpion Therapeutics, Servier, Sotio Biotech, Taiho, Takeda Oncology and Tolremo Therapeutics. Stocks: Oniria Therapeutics, Alentis Therapeutics, Pangaea Oncology and 1TRIALSP. – A.P.G. reports financial interests in Oniria Therapeutics and Peptomyc. – J.L. receives honoraria from MSD, is consulting or has advisory role in Tailho Pharmaceutical. Her institution is consulting or has advisory in Starpharma, Greywolf Therapeutics. Her institution receives research funding from Starpharma, Corvus Pharmaceuticals, Relay Therapeutics, ALX Oncology, IDEAYA Biosciences, Innovent Biologics, Greywolf Therapeutics, MSD, Regeneron, Bristol Myers Squibb, Abbvie, AVEO, Bayer, Merus, Nested Therapeutics, Carina Biotech, ImmVirX. J.L. receives travel, accommodation and expenses support from Starpharma, ImmVirX, MSD, Innovent Biologics. – Sa.I. has received research funding from Canon Medical, Hitachi Systems, ACT Genomics, AMED, as well as speaker fees and advisory board for Pfizer, AstraZeneca, Guardant Health, Guardant Health AMEA, Roche, Chugai Pharmaceutical, Shionogi, Taiho, IQVIA, Bayer, ACT Med, Novartis, Molecular Health, MSD, Merck, and Sysmex; is a co-founder of AIM Precision Therapeutics. – A.M.T. declares receipt of Clinical Trial Research Funding (received through the institution): OBI Pharma, Agenus, Vividion, Macrogenics, AbbVie, IMMATICS, Novocure, Tachyon, Parker Institute for Cancer Immunotherapy, Tempus, and Tvardi; fees for consulting or advisory roles for Avstera Therapeutics, Bioeclipse, BrYet, Diaccurate, Macrogenics, NEX-I, and VinceRx. – D.S.D. declares consulting for AstraZeneca, Clovis (Change&), GSK (DSMB), Puma (disparities), Immunogen (social media). D.S.D.’s institution receives funding for IST from Bristol Myers Squibb. – R.S. reports: Esteve (invited speaker, personal), SACE Medhealth (commercial medical education company owned by wife until December 2023), TDD (Member of the Executive Committee – no financial interest), WNT Pharma (coordinating PI, personal and institutional, financial interest). – E.F. reports receipt of personal honoraria for advisory board participation from Abbvie, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, BMS, Daiichi Sankyo, F. Hoffmann-La Roche, Genmab, Gilead, GSK, ITeos Theraputics, Janssen, Johnson & Johnson, MSD, Novartis, Pierre Fabre, Pfizer, Regeneron, Turning Point, Daiichi Sankyo; personal speaker honoraria from Amgen, AstraZeneca, BMS, Daiichi Sankyo, Eli Lilly, F. Hoffmann-La Roche, Johnson & Johnson, Genentech, Gilead, Janssen, Medical Trends, Medscape, Merck Serono, MSD, Novartis, Peervoice, Pierre Fabre, Pfizer, Regeneron, Touch Oncology; Board of Director role: Grifols; financial support for meeting attendance and/or travel from AstraZeneca, Janssen, Roche. – J.B. reports: Advisor: AbbVie, Amgen, AstraZeneca, Bayer, Beigene, MSD, Merck-Serono, Roche, Takeda; Writing/speaker engagement: BMS, Medison, Pfizer. Research funding: Immunai, OncoHost, MSD, AstraZeneca, Roche, Abbvie. – A.M.J. reports stock and other ownership interest in Pricilium Therapeutics. A.M.J.’s institution reports consulting or advisory role in Janssen Oncology, Ipsen, AstraZeneca, Sanofi, Pfizer, Novartis, Merck Serono, Ideaya, IQvia, Bayer, Astellas Pharma, Grey Wolf Therapeutics, Medison, Starpharma, Eisai, Mayne Pharma and MSD Oncology; Research funding from Bristol-Myers Squibb, Janssen Oncology, Merck Sharp & Dohme, Mayne Pharma, Roche/Genentech, Bayer, Lilly, Pfizer, AstraZeneca, Corvus Pharmaceuticals, Lilly, Genentech, BeiGene, Myeloid Therapeutics and Immunocore. A.M.J. reports patients, rolyalties or other intellectual property in Cancer therapeutic methods. – M.E.S. reports consulting or advisory roles in Taiho Pharmaceutical, Exelixis, Bristol Myers Squibb, Exelixis, QED Therapeutics, Novartis and Pfizer; Speakers’ Bureau: Taiho Pharmaceutical, Daiichi Sankyo/Astra Zeneca, BMS, Merck (none in 2024). – Se.L. is an employee of Sir H N Reliance Foundation Hospital and Research Centre. Se.L. Has a leadership role in Sir H N Reliance Foundation Hospital and Research Centre and Nova Precision AI, IMPACT India International MTB, is Co-Chair of Asia Pacific Coalition against Lung Cancer and Member WIN Consortium in Precision Oncology. Se.L. reports stock or other ownership interest in Nova Precision AI and is co-founder. Se.L. has consulting or advisory roles in AstraZeneca, Bristol-Myers Squibb, MSD, Boehringer Ingelheim, Merck, Roche and Novartis. Se.L. Reports speakers’ bureau from AstraZeneca, MSD, Bristol-Myers Squibb, Boehringer Ingelheim, Merck, Roche and Novartis. – I.A.G receives honoraria from AstraZeneca. – R.S.H. is on the Board of Directors of Immunocore and Junshi Pharmaceuticals and in a leadership role at Friends of Cancer, American Association for Cancer Research, International Association for the Study of Lung Cancer, Southwest Oncology Group. – R.S.H. is consulting or has advisory role and receives consulting fees in Junshi Pharmaceuticals, AstraZeneca, Amgen, ArriVent, Bristol-Myers Squibb, Candel Therapeutics, Inc., Catalym, Checkpoint Therapeutics, Cybrexa Therapeutics, Eli Lilly and Company, Genentech, Gilead, I-Mab Biopharma, Janssen, Mediflix, Merck and Company, Neuvogen, NextCure, Normunity, Novartis, Pfizer, Regeneron Pharmaceuticals, Roche, Sanofi. – R.S.H. reports stock and other ownership interests in Immunocore, Checkpoint Therapeutics, and Normunity. – R.S.H has received research support from Eli Lilly and Company. – R.S.H. has received travel support from AstraZeneca, Friends of Cancer, Genentech, Merck and Company, American Association for Cancer Research, International Association for the Study of Lung Cancer, and Southwest Oncology Group. – G.R. served on advisory boards for AstraZeneca, Pfizer, and Bayer in the past 2 years.